Intracranial Hemorrhage

In a retrospective cohort study, patients with atrial fibrillation who were treated with apixaban experienced lower incidence of ischemic stroke, systemic embolism and bleeding compared with patients who received rivaroxaban.

Among patients with acute stroke and large-vessel occlusion, adding IV thrombolysis to endovascular therapy may not be necessary, according to findings presented at the International Stroke Conference.

During the 5 years after a stroke, targeting LDL of less than 70 mg/dL prevented more than one-quarter of major CV events, recurrent cerebral infarction or urgent carotid revascularization and recurrent cerebral infarction or hemorrhage vs. an LDL target of less than approximately 100 mg/dL.

PHILADELPHIA — Among patients with signs of atherosclerosis following stroke or transient ischemic attack, those who achieved a target LDL level of less than 70 mg/dL had lower risk for subsequent CV events than patients achieving LDL levels between 90 and 110 mg/dL, according to findings presented at the American Heart Association Scientific Sessions.

Older patients with atrial fibrillation were more likely to have high bleeding risk contraindications with oral anticoagulation and higher mortality compared with patients who were not treated with oral anticoagulation and did not have contraindications, according to a observational, longitudinal analysis published in JACC: Clinical Electrophysiology.